Compare Abeona Therapeutics Inc (ABEO) vs NetApp Inc. (NTAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs NetApp Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while NetApp Inc. trades at $163.56 (market cap $32.48B). The key difference: NetApp Inc. is far larger — about 87× Abeona Therapeutics Inc's market cap, and NetApp Inc. pays a 1.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NTAP | |
|---|---|---|
Market Cap | $373.32M | $32.48B |
Sector | Health | Technology |
52-Week High | $7.23 | $181.08 |
52-Week Low | $4.17 | $94.11 |
Enterprise Value | $228.22M | $31.63B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NTAP trades at $165.78, up 7.53% in the last session, near its consensus price target of $167.45. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical signals from moving averages. Revenue grew to $6.57B in 2025 with an 18.43% net income margin, while cash flow turned positive at $840M. Recent news highlights AI-driven growth opportunities and strategic partnerships enhancing its data infrastructure offerings.
The outlook remains positive given AI demand tailwinds and solid execution, though valuation multiples are elevated. Key risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus leans neutral with a slight buy bias, suggesting cautious optimism for further upside if growth sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
